Search Results - "Orozco, Jennifer S"

Cobimetinib‐induced “dropped head syndrome” and subsequent disease management in an Erdheim‐Chester patient by King, Amber C., Diamond, Eli L., Orozco, Jennifer S., Morse, Hannah R., Ouyang, Linda L., Schöder, Heiko, Rampal, Raajit K.

“…Our rechallenge of cobimetinib in an Erdheim‐Chester Disease (ECD) patient for the rare adverse effect, “dropped head syndrome,” with a previously unexplored…”
Get full text

Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma by King, Amber C, Orozco, Jennifer S

“…Axicabtagene ciloleucel (axi-cel) is an anti-CD19 CAR T-cell therapy that has demonstrated efficacy in relapsed and refractory diffuse large B-cell lymphoma…”
Get full text

Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi‐institutional experience by Mohan, Meera, Becnel, Melody Renee, Shah, Urvi A., Dong, Huaying, Gundarlapalli, Sravani, Peterson, Timothy, Orozco, Jennifer S., Horowitz, Sandra, Chhabra, Saurabh, Dhakal, Binod, Thanendrarajan, Sharmilan, Radhakrishnan, Sabarinath Venniyil, Al Hadidi, Samer, Tan, Carlyn, Mailankody, Sham, Hultcrantz, Malin, Korde, Neha, Hassoun, Hani, Lesokhin, Alexander M., Thomas, Sheeba K., Patel, Krina K., Manasanch, Elisabet E., Weber, Donna M., Szabo, Aniko, Kaufman, Gregory P., Lee, Hans C., Zangari, Maurizio, Rhee, Frits, Usmani, Saad Z., D'Souza, Anita, Orlowski, Robert Z., Schinke, Carolina

Get full text

Outpatient clinical pharmacy practice in the face of COVID-19 at a cancer center in New York City by Yerram, Prakirthi, Thackray, Jennifer, Modelevsky, Lisa R, Land, Josiah D, Reiss, Samantha N, Spatz, Krisoula H, Levoir, Andrea C, Pak, Terry K, Dao, Phuong H, Buege, Michael J, Derespiris, Lauren M, Lau, Carmen, Orozco, Jennifer S, Boparai, Manpreet, Koranteng, Lauren A, Reichert, Kate E, Yan, Shirley Q, Daukshus, Nicole P, Mathew, Sherry, Buie, Larry W, Tizon, Richard F, Freeswick, Scott, Liu, Dazhi, Harnicar, Stephen

“…Purpose With the rapid spread of COVID-19 in New York City since early March 2020, innovative measures were needed for clinical pharmacy specialists to provide…”
Get full text

Busulfan/Melphalan/Fludarabine (Bu/Mel/Flu) Conditioning Versus Total Body Irradiation/Thiotepa/Cyclophosphamide (HFTBI/Thio/Cy) Based Conditioning in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Undergoing CD34-Selected T-Cell Depleted Allogeneic Stem Cell Transplantation (alloSCT) by Orozco, Jennifer S., Hilden, Patrick, Maloy, Molly A., Pappacena, Jeremy, Buie, Larry W., Shaffer, Brian C., Papadopoulos, Esperanza B., Jakubowski, Ann A., Bhatt, Valkal

“…In patients with poor risk AML or MDS in first complete remission (CR1), alloSCT can be potentially curative. Comparison of the non-hematologic toxicities…”
Get full text

Cobimetinib-induced "dropped head syndrome" and subsequent disease management in an Erdheim-Chester patient by King, Amber C, Diamond, Eli L, Orozco, Jennifer S, Morse, Hannah R, Ouyang, Linda L, Schöder, Heiko, Rampal, Raajit K

Get full text